The EUROPEAN EMA's Human Medicines Committee (CHMP) recommended eight drugs for approval at its April 2020 meetingCHMP recommends a fixed dose combination of Enerzair breezhaler (indacaterol/glycopyrronium/mometasone) and an inhaler for the treatment of asthmaCHMP also recommends that Zimbus Breezhaler (indacaterol/glycopyrronium/mometasone) also be used to treat asthmaCHMP recommends granting the Hedgehog signaling pathway inhibitor Daurismo (glasdegib) a market license for the treatment of acute myeloid leukemiaCHMP recommends that refoamer Reblozyl (luspatercept) of red blood cell maturation should be used to treat adult patients with blood transfusion-dependent anemia associated with bone marrow hyperplasia syndrome or beta-thalassemiaCHMP recommends using the biosimilar insulin aspart Sanofi (men's winter insulin) to treat diabetesCHMP recommends granting Cabazitaxel Accord a sales license to treat patients with metastatic prostate cancer who have previously been treated with hormones containing polysequinolCHMP recommends that Paliperidone Janssen-Cilag International be used to treat schizophreniaCHMP recommends using the generic drug Fingolimod Accord to treat recurrent and remission-relieving multiple sclerosis with high disease activity
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
